SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-041588
Filing Date
2021-08-05
Accepted
2021-08-05 16:11:29
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kura-8k_20210805.htm   iXBRL 8-K 39264
2 EX-99.1 kura-ex991_6.htm EX-99.1 166474
3 GRAPHIC g0iyjjtccmii000001.jpg GRAPHIC 11315
  Complete submission text file 0001564590-21-041588.txt   363024

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kura-20210805.xsd EX-101.SCH 5792
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kura-20210805_lab.xml EX-101.LAB 19469
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kura-20210805_pre.xml EX-101.PRE 11642
7 EXTRACTED XBRL INSTANCE DOCUMENT kura-8k_20210805_htm.xml XML 3559
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

IRS No.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 211148278
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences